Firm will contribute potential cannabinoid treatments to ongoing study being conducted by the Foundation.

Cannabis Science is partnering with The Unconventional Foundation for Autism (UF4A) to build on the Foundation’s success with cannabinoid formulations for autism treatment. They will work together to advance cannabis treatments for autism.

UF4A was established by Mieko Hester Perez after her son, Joey, was diagnosed with autism. After prescription drug cocktails did not work and Joey was given six months to live at 10 years of age, she found that medicinal marijuana helped.

The foundation aims to raise awareness and support for patients and their families, to raise funds for cannabis-based medical research and clinical trials, and to campaign for a rescheduling of cannabis from Schedule 1 narcotic (no accepted medical benefits) to a lower schedule so that the appropriate research may be conducted and so that all patients have access to medication.

“We believe that this new partnership with Cannabis Science will give us additional push and resources required to advance our autism research,” Perez says. “To date, we have already partnered with the University of California Irvine Medical Center to oversee our cannabis-based autism research.” UCI is documenting a study comprising Joey and 10 other families.

As part of the new partnership, Robert Melamede, Ph.D., CEO of Cannabis Science, will join the board of UF4A as a scientific advisor. He will work with the foundation to further assist in documenting the case studies and oversee the deployment of the company’s cannabinoid treatments on autism patients alongside UF4A and medical professionals. He will also work with UF4A’s legal advisors to progress the legalization of medical marijuana initiatives.

“The successful results from the autism patients treated as documented by UF4A are very encouraging, and we’re excited to tap into UF4A’s proven track record, providing our scientific expertise to help develop more refined treatment plans with Cannabis Science’s formulations and extracts to achieve scientifically accepted patient outcomes,” states Dr. Melamede.

Cannabis Science focuses on phytocannabinoid science. Phytocannabinoids are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin produced in trichomes and are most prevalent in the flowers of the female plants.

Previous articleResearchers Break Cancer Cells’ Mucus Barrier to Study Cytotoxic Therapies
Next articleSanofi-Aventis Taps Epistem to Inform Biomarker Strategy for Cancer Drug Development